Pharmacological treatment of obesity in children and adolescents: Current status and perspectives

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 18, 2010, Pages 2973-2983

  Catoira, Natalia ^a   Nagel, Mara ^b   Di Girolamo, Guillermo ^a,c   Gonzalez, Claudio D ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD AUSTRAL   (Argentina)

^c FAVALORO UNIVERSITY   (Argentina)

Author keywords

Adolescents; Children; Drugs; Obesity; Treatment

Indexed keywords

AMFEBUTAMONE; AMYLIN; ANTICONVULSIVE AGENT; ANTIOBESITY AGENT; BIGUANIDE; CETILISTAT; EMPATIC; EXENDIN 4; INCRETIN; LAMOTRIGINE; LIRAGLUTIDE; LORCASERIN; METFORMIN; METRELEPTIN; MONOAMINE OXIDASE INHIBITOR; NALTREXONE; OLANZAPINE; PEPTIDE YY; PEPTIDE YY [3-36]; PHENTERMINE; PRAMLINTIDE; QNEXA; QUETIAPINE; RISPERIDONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; ZONISAMIDE;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; BLOOD PRESSURE; BODY MASS; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIET THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPOGLYCEMIA; INSOMNIA; LIFESTYLE MODIFICATION; NAUSEA; OBESITY; PRACTICE GUIDELINE; PRESCHOOL CHILD; PREVALENCE; REVIEW; SCHOOL CHILD; SIDE EFFECT; STEATORRHEA; SUICIDAL IDEATION; TACHYCARDIA; VOMITING; WAIST CIRCUMFERENCE; XEROSTOMIA;

ADOLESCENT; ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CHILD; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; LIFE STYLE; OBESITY; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 78649256872     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.512005     Document Type: Review

References (57)

1. Daniels SR, Arnett DK, Eckel RH, et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005;111(15):1999-2012 • This paper gives cites on obesity burden in the world.
2. Godoy-Matos AF, Guedes EP, Souza LL, Martins MF. Management of obesity in adolescents: state of art. Arq Bras Endocrinol Metabol 2009;53(2):252-61
3. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320(7244):1240-3
4. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010;303(3):242-9
5. Shields M, Tremblay MS. Canadian childhood obesity estimates based on WHO, IOTF and CDC cut-points. Int J Pediatr Obes 2010;5(3):265-73
6. Crocker MK, Yanovski JA. Pediatric obesity: etiology and treatment. Endocrinol Metab Clin North Am 2009;38(3):525-48
7. Barlow SE. Expert committee recommendations regarding the prevention, assessment and treatment of child and adolescents overweight and obesity: summary report. Pediatrics 2007;120(Suppl 4):S164-92
8. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21(Suppl 3):S12-23 • This article provides information on orlistat mode of action and pharmacokinetics.
9. Carriere F, Renou C, Ransac S, et al. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2001;281:16-28
10. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999;39(1):41-6
11. Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60 mg, over-the-counter dosage. Expert Opin Pharmacother 2007;8:1733-42
12. Rogovik AL, Chanoine JP, Goldman RD. Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity. Drugs 2010;70(3):335-46 •• This paper provides an accurate review of clinical trials and meta-analysis involving orlistat.
13. Viner RM, Hsia Y, Tomsic T, Wong IC. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Obes Rev 2009. [Epub ahead of print]
14. Singhal V, Schwenk WF, Kumar S. Evaluation and management of Childhood and adolescent obesity. Mayo Clin Proc 2007;82(10):1258-64
15. McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002;22(7):814-22
16. Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003;22(5):357-62
17. Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004;163(12):738-41
18. McDuffie JR, Calis KA, Uwaifo GI, et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004;17(3):307-19
19. Norgren S, Danielsson P, Jurold R, et al. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr 2003;92(6):666-70
20. Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005;293(23):2873-83
21. Maahs D, de Serna DG, Kolotkin RL, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006;12(1):18-28
22. Fabricatore AN, Wadden TA, Moore RH, et al. Attrition from Randomized Controlled Trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev 2009;10(3):333-41
23. Fujita Y, Hosokawa M, Fujimoto S, et al. Metformin suppresses hepatic gluconeogenesis and lowers fasting blood glucose levels through reactive nitrogen species in mice. Diabetologia 2010;53(7):1472-81 • This article gives complete information on mode of action of metformin.
24. Hou X, Song J, Li XN, et al. Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun 2010;396(2):199-205
25. Wong AK, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) 2009;116(8):607-20
26. Foss MT, Clement KD. Metformin as a cause of late-onset chronic diarrhea. Pharmacotherapy 2001;21(11):1422-24
27. Chau-Van C, Gamba M, Salvi R, et al. Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide y expression in cultured hypothalamic neurons. Endocrinology 2007;148(2):507-11
28. Romualdi D, De Marinis L, Campagna G, et al. Alteration of ghrelin-neuropeptide y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. Clin Endocrinol (Oxf) 2008;69(4):562-7
29. Aubert G, Mansuy V, Voirol MJ, et al. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism 2010. [Epub ahead of print]
30. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30(5):359-71
31. Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50(12):1457-61
32. Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006;91(6):2074-80
33. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2008;21(4):339-48 • This is an interesting clinical trial involving the use of metformin in obese adolescents with hyperinsulinemia.
34. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008;152(6):817-22
35. Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163(12):2072-9
36. Lean ME. How does sibutramine work? Int J Obes Relat Metab Disord 2001;25(Suppl 4):S8-11 • This article gives complete information on mode of action and pharmacokinetics of sibutramine.
37. Ledonne A, Sebastianelli L, Federici M, et al. The anorexic agents, sibutramine and fenfluramine, depress GABA (B)-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells. Br J Pharmacol 2009;156(6):962-9
38. Liu YL, Heal DJ, Stock MJ. Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. Int J Obes Relat Metab Disord 2002;26(9):1245-53
39. Berkowitz RI, Fujioka K, Daniels SR, et al.; Sibutramine Adolescent Study Group. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006;145(2):81-90 •• This is an interesting clinical trial involving the use of sibutramine in the treatment in obese adolescents.
40. Ryan DH. Clinical use of sibutramine. Drugs Today (Barc) 2004;40(1):41-54
41. Reisler G, Tauber T, Afriat R, et al. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. Isr Med Assoc J 2006;8(1):30-2
42. Garcia-Morales LM, Berber A, Macias-Lara CC, et al. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2006;28(5):770-82
43. Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. Clin Endocrinol Metab 2005;90(3):1460-65
44. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003;289(14):1805-12
45. Daniels SR, Long B, Crow S, et al.; Sibutramine Adolescent Study Group. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics 2007;120(1):147-57
46. Alterio V, Monti SM, Truppo E, et al. The first example of a significant active site conformational rearrangement in a carbonic anhydrase-inhibitor adduct: the carbonic anhydrase I-topiramate complex. Org Biomol Chem 2010. [Epub ahead of print] • This paper provides information on novel agents in development.
47. Ghanizadeh A. Loss of taste and smell during treatment with topiramate. Eat Weight Disord 2009;14(2-3):137-8
48. Li HF, Zou Y, Xia ZZ, et al. Effects of topiramate on weight and metabolism in children with epilepsy. Acta Paediatr 2009;98(9):1521-5
49. Fernandez-Mayoralas DM, Fernandez-Jaen A, Jareno NM, et al. Meralgia paresthetica in the pediatric population: a propos of 2 cases. J Child Neurol 2010;25(1):110-13
50. Klonoff DC, Greenway F. Drugs in the pipeline for the obesity market. Diab Sci Technol 2008;2(5):913-18
51. Shank RP, Smith-Swintosky VL, Maryanoff BE. Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem 2008;23(2):271-6
52. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10(7):633-41
53. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-HT2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325(2):577-87
54. Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007;31(3):494-9
55. Rodriguez LM, Mason KJ, Haymond MW, Heptulla RA. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes. Pediatr Res 2007;62(6):746-9
56. Stoeckel LE, Weller RE, Giddings M, Cox JE. Peptide YY levels are associated with appetite suppression in response to long-chain fatty acids. Physiol Behav 2008;93(1-2):289-95
57. Suzuki K, Simpson KA, Minnion JS, et al. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 2010;57(5):359-72